Literature DB >> 33413835

Non-Vitamin K Antagonist Oral Anticoagulants in Elderly (≥85 years) Patients With Newly Diagnosed Atrial Fibrillation: Changing Clinical Practice and Outcomes for Stroke Prevention in a Nationwide Cohort Study.

Wen-Han Cheng1, Chern-En Chiang2, Yenn-Jiang Lin1, Shih-Lin Chang1, Li-Wei Lo1, Yu-Feng Hu1, Ta-Chuan Tuan1, Jo-Nan Liao1, Fa-Po Chung1, Tzeng-Ji Chen3, Gregory Y H Lip4, Shih-Ann Chen5, Tze-Fan Chao6.   

Abstract

OBJECTIVE: To investigate the influences of non-vitamin K antagonist oral anticoagulants (NOACs) on rates of initiations of oral anticoagulants (OACs) and outcomes among elderly patients with atrial fibrillation (AF).
METHODS: From January 1, 2009, to December 31, 2015, 33,539 newly-diagnosed AF patients older than 85 years old who survived more than 180 days after AF diagnosis were studied. Temporal trends regarding OAC initiation rates after incident AF were analyzed. The 1-year risks of ischemic stroke, intracranial hemorrhage, and mortality of incident AF patients diagnosed each year were compared with that of the year 2009.
RESULTS: Initiation rates of OACs after AF was newly diagnosed in the elderly significantly increased from 9.5% to 34.3%, mainly due to the introduction of NOACs (from 0% to 26.2%). Several clinical factors were associated with OACs underuse, including chronic obstructive pulmonary disease, abnormal renal function, anemia, and history of bleeding. Compared with year 2009 (incidence rate, 5.55%/year), the 1-year risk of ischemic stroke after AF diagnosis decreased in the era of NOACs (incidence rate, 4.20%/year; adjusted hazard ratio [aHR], 0.748 in year 2012; 4.39%/year, aHR, 0.789 in 2014; 2.75%/year; aHR, 0.513 in year 2015; all P<.01, except for year 2013, 4.80%/year [P=.07]). Also, the risks of mortality were lower in years 2012 to 2015, while the risk of ICH remained unchanged.
CONCLUSION: Initiation rates of OACs after AF was newly diagnosed in the elderly significantly increased following the introduction of NOACs. A lower risk of ischemic stroke, mortality, and composite adverse events was observed, which was temporally associated with the increasing prescription rates of OACs.
Copyright © 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33413835     DOI: 10.1016/j.mayocp.2020.08.042

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  6 in total

1.  Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants.

Authors:  Jo-Nan Liao; Yi-Hsin Chan; Ling Kuo; Chuan-Tsai Tsai; Su-Shen Lim; Tze-Fan Chao
Journal:  Front Cardiovasc Med       Date:  2022-07-05

2.  Impact of anemia on clinical outcomes of patients with atrial fibrillation: The COOL-AF registry.

Authors:  Rungroj Krittayaphong; Satchana Pumprueg; Tomon Thongsri; Weerapan Wiwatworapan; Thaworn Choochunklin; Pontawee Kaewkumdee; Ahthit Yindeengam
Journal:  Clin Cardiol       Date:  2021-02-04       Impact factor: 3.287

3.  Outcome of Elderly Patients with Venous Thromboembolism Treated with Direct Oral Anticoagulants-A Retrospective Cohort Study.

Authors:  Irit Ayalon-Dangur; Yakov Vega; Miriam Rozi Israel; Alon Grossman; Galia Spectre; Tzippy Shochat; Leonard Leibovici; Anat Gafter-Gvili
Journal:  J Clin Med       Date:  2021-12-01       Impact factor: 4.241

4.  Modified Taiwan Atrial Fibrillation Score for the Prediction of Incident Atrial Fibrillation.

Authors:  Jo-Nan Liao; Su-Shen Lim; Tzeng-Ji Chen; Ta-Chuan Tuan; Shih-Ann Chen; Tze-Fan Chao
Journal:  Front Cardiovasc Med       Date:  2022-01-28

5.  Clinical features and outcomes of patients in different age groups with non-valvular atrial fibrillation receiving oral anticoagulants.

Authors:  U Fan O; Tou Kun Chong; Yulin Wei; Bishow Paudel; Michael C Giudici; Chi Wa Wong; Wai Kit Lei; Jian Chen; Wei Wu; Kan Liu
Journal:  Int J Cardiol Heart Vasc       Date:  2022-03-28

6.  Oral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation.

Authors:  Alexandros A Polymeris; Kosmas Macha; Maurizio Paciaroni; Duncan Wilson; Masatoshi Koga; Manuel Cappellari; Sabine Schaedelin; Annaelle Zietz; Nils Peters; David J Seiffge; David Haupenthal; Luise Gassmann; Gian Marco De Marchis; Ruihao Wang; Henrik Gensicke; Svenja Stoll; Sebastian Thilemann; Nikolaos S Avramiotis; Bruno Bonetti; Georgios Tsivgoulis; Gareth Ambler; Andrea Alberti; Sohei Yoshimura; Martin M Brown; Masayuki Shiozawa; Gregory Y H Lip; Michele Venti; Monica Acciarresi; Kanta Tanaka; Maria Giulia Mosconi; Masahito Takagi; Rolf H Jäger; Keith Muir; Manabu Inoue; Stefan Schwab; Leo H Bonati; Philippe A Lyrer; Kazunori Toyoda; Valeria Caso; David J Werring; Bernd Kallmünzer; Stefan T Engelter
Journal:  Ann Neurol       Date:  2021-11-29       Impact factor: 11.274

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.